Trial Profile
Rapidity of onset of response to Adalimumab in luminal Crohn's disease. RAPIDA study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms RAPIDA
- Sponsors AbbVie
- 01 Nov 2017 Results evaluating the rapidity of onset of clinical response to ADA therapy presented at the 25th United European Gastroenterology Week
- 02 Feb 2017 Status changed from active, no longer recruiting to completed.
- 02 Nov 2016 Planned End Date changed from 1 Mar 2017 to 1 Jan 2017.